— First-in-human Phase 1 trial for lead program, BMB-101, a highly selective 5-HT2C agonist, is underway in Australia — — Company has transitioned from a discovery to a development organization – — Company to attend BIO-Europe Spring Conference in Basel, Switzerland, March 20-22, 2023 — VANCOUVER, British Columbia, Feb. 27, 2023 (GLOBE NEWSWIRE) — Bright Minds Biosciences Inc. (CSE:DRUG)…


Previous articleLooking Ahead to a Psychedelic 2023
Next articleCOMPASS Pathways Announces Fourth Quarter and Year-End 2022 Financial Results and Business Highlights